InflaRx Announces Full-Year 2024 Results Timeline
InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical pioneer in anti-inflammatory therapies, has revealed plans to publish its financial and operational results for the fourth quarter and full year of 2024 on March 20, 2025. This announcement comes as the company focuses on advancing its innovative treatments targeting the complement system, which plays a significant role in inflammatory diseases.
Investor Conferences Participation
In addition to its financial disclosure, InflaRx will actively engage with investors during two upcoming conferences. This participation underscores the company’s commitment to transparency and investor relationship management as it navigates the biopharmaceutical landscape.
Upcoming Conferences
The first event is the Leerink Global Healthcare Conference, scheduled from March 9 to 12, 2025, in Miami Beach. InflaRx will conduct a fireside chat there on March 10 at 10:40 AM ET, providing attendees an opportunity to gain insights into the company's strategic vision and direction. Furthermore, one-on-one meetings will be available to foster deeper investor engagement.
Virtual Conference Details
Following this, InflaRx will also participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference on March 27, 2025. The company will hold a virtual fireside chat at 8:30 AM ET, aimed at sharing valuable updates and answering questions from the investment community.
About InflaRx
Founded in 2007, InflaRx is at the forefront of developing groundbreaking treatments aimed at controlling inflammation through its proprietary anti-C5a and anti-C5aR technologies. The company specializes in discovering and commercializing potent inhibitors targeting the complement activation factor C5a and its receptor C5aR, which are critical players in various inflammatory conditions.
Innovative Product Pipeline
The lead candidate, vilobelimab, is recognized as a first-in-class, intravenously administered anti-C5a monoclonal antibody. With its ability to selectively bind to free C5a, it has shown promise in clinical studies, demonstrating disease-modifying activity and a favorable safety profile. Additionally, InflaRx is developing INF904, an orally administered small molecule that targets the C5a receptor, further diversifying its treatment offerings.
Global Presence and Commitment
With headquarters in Jena, Germany, along with subsidiaries in Munich and Ann Arbor, MI, InflaRx continues to expand its reach and capabilities. The company remains dedicated to enhancing the lives of patients suffering from inflammatory diseases by delivering innovative treatment options. For more information, interested parties can visit the company's website.
Contact Information
For inquiries related to investor relations, InflaRx can be contacted through its Vice President, Jan Medina, CFA, at IR@inflarx.de. Additional support can be reached through its partner MC Services AG for any European investor inquiries, with communication handled by Katja Arnold, Laurie Doyle, and Dr. Regina Lutz amongst others, at inflarx@mc-services.eu.
Frequently Asked Questions
What is InflaRx preparing to announce on March 20, 2025?
InflaRx will report its financial and operational results for the fourth quarter and full year 2024.
What conferences will InflaRx attend in March?
InflaRx will participate in the Leerink Global Healthcare Conference and the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference.
What products are currently in InflaRx's pipeline?
The lead product is vilobelimab, an anti-C5a monoclonal antibody, along with INF904, an oral C5a receptor inhibitor.
Where is InflaRx headquartered?
InflaRx is headquartered in Jena, Germany, with additional offices in Munich and Ann Arbor, MI, USA.
Who should be contacted for investor relations inquiries?
Jan Medina, CFA, the Vice President of Investor Relations, can be contacted at IR@inflarx.de for inquiries.
